306 related articles for article (PubMed ID: 30791097)
21. Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study.
Bidard FC; Hajage D; Bachelot T; Delaloge S; Brain E; Campone M; Cottu P; Beuzeboc P; Rolland E; Mathiot C; Pierga JY
Breast Cancer Res; 2012 Feb; 14(1):R29. PubMed ID: 22330883
[TBL] [Abstract][Full Text] [Related]
22. CYFRA 21-1 as a tumor marker for squamous cell carcinoma of the esophagus.
Nakamura T; Ide H; Eguchi R; Hayashi K; Takasaki K; Watanabe S
Dis Esophagus; 2017 Nov; 11(1):35-39. PubMed ID: 29040480
[TBL] [Abstract][Full Text] [Related]
23. Monitoring of therapy in head and neck patients during the radiotherapy by measurement of Cyfra 21-1.
Pradier O; Hille A; Schmiberger H; Hess CF
Cancer Radiother; 2002 Feb; 6(1):15-21. PubMed ID: 11899676
[TBL] [Abstract][Full Text] [Related]
24. Relationship between pretreatment levels of serum Cyfra 21.1, CEA and PET metabolic parameters in NSCLC.
Dogan I; Karyagar S; Karyagar SS; Kahraman C; Alver A
Ann Nucl Med; 2014 Nov; 28(9):829-35. PubMed ID: 24990528
[TBL] [Abstract][Full Text] [Related]
25. [Usefulness of the SCC, CEA, CYFRA 21.1, and CRP markers for the diagnosis and monitoring of cervical squamous cell carcinoma].
Chmura A; Wojcieszek A; Mrochem J; Walaszek-Gruszka A; Deja R; Masłyk B; Bartnik W; Sodowski K
Ginekol Pol; 2009 May; 80(5):361-6. PubMed ID: 19548456
[TBL] [Abstract][Full Text] [Related]
26. Extramammary Paget's disease: treatment, prognostic factors and outcome in 76 patients.
Hatta N; Yamada M; Hirano T; Fujimoto A; Morita R
Br J Dermatol; 2008 Feb; 158(2):313-8. PubMed ID: 18028492
[TBL] [Abstract][Full Text] [Related]
27. MiR-155, a potential serum marker of extramammary Paget's disease.
Guo H; Qi RQ; Sheng J; Liu C; Ma H; Wang HX; Li JH; Gao XH; Wan YS; Chen HD
BMC Cancer; 2018 Nov; 18(1):1078. PubMed ID: 30458743
[TBL] [Abstract][Full Text] [Related]
28. Measurement of serum carcinoembryonic antigen, carbohydrate antigen 19-9, cytokeratin-19 fragment and matrix metalloproteinase-7 for detecting cholangiocarcinoma: a preliminary case-control study.
Lumachi F; Lo Re G; Tozzoli R; D'Aurizio F; Facomer F; Chiara GB; Basso SM
Anticancer Res; 2014 Nov; 34(11):6663-7. PubMed ID: 25368272
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of cytokeratin 19 fragment (CYFRA 21-1) as a tumor marker in malignant pleural effusion.
Lai RS; Chen CC; Lee PC; Lu JY
Jpn J Clin Oncol; 1999 Sep; 29(9):421-4. PubMed ID: 10563194
[TBL] [Abstract][Full Text] [Related]
30. Neutrophil-to-lymphocyte ratio is a potential prognostic biomarker for extramammary Paget disease: A retrospective study.
Maeda T; Uehara J; Toyoshima R; Nakagawa T; Yoshino K
J Dermatol; 2022 Nov; 49(11):1188-1192. PubMed ID: 35903974
[TBL] [Abstract][Full Text] [Related]
31. Cytokeratin fragment 19 (CYFRA 21-1) and carcinoembryonic antigen for early prediction of recurrence of lung adenocarcinoma.
Kao CH; Hsieh JF; Ho YJ; Ding HJ
Lung; 1999; 177(5):333-7. PubMed ID: 10467024
[TBL] [Abstract][Full Text] [Related]
32. Expression of laminin-5 gamma 2 chain predicts invasion of extramammary Paget's disease cell.
Tohmatsu Y; Imura J; Sakai T; Takagi K; Minamisaka T; Tanaka S; Noguchi A; Nakajima T; Nagata T; Makino T; Shimizu T; Fujii T
APMIS; 2021 Jan; 129(1):3-8. PubMed ID: 32996218
[TBL] [Abstract][Full Text] [Related]
33. CYFRA 21-1 as a Predictive Marker for Non-small Cell Lung Cancer Treated with Pemetrexed-based Chemotherapy.
Sone K; Oguri T; Nakao M; Kagawa Y; Kurowaka R; Furuta H; Fukuda S; Uemura T; Takakuwa O; Kanemitsu Y; Ohkubo H; Takemura M; Maeno K; Ito Y; Sato H; Muramatsu H; Niimi A
Anticancer Res; 2017 Feb; 37(2):935-939. PubMed ID: 28179355
[TBL] [Abstract][Full Text] [Related]
34. Screening values of carcinoembryonic antigen and cytokeratin 19 fragment for lung cancer in combination with low-dose computed tomography in high-risk populations: Initial and 2-year screening outcomes.
Triphuridet N; Vidhyarkorn S; Worakitsitisatorn A; Sricharunrat T; Teerayathanakul N; Auewarakul C; Chungklay N; Krongthong W; Luengingkasoot S; Sornsamdang G; Patumanond J; Sritipsukho P
Lung Cancer; 2018 Aug; 122():243-248. PubMed ID: 30032839
[TBL] [Abstract][Full Text] [Related]
35. Clinical and pathological characteristics of extramammary Paget's disease: report of 246 Chinese male patients.
Kang Z; Zhang Q; Zhang Q; Li X; Hu T; Xu X; Wu Z; Zhang X; Wang H; Xu J; Xu F; Guan M
Int J Clin Exp Pathol; 2015; 8(10):13233-40. PubMed ID: 26722523
[TBL] [Abstract][Full Text] [Related]
36. The expression of HER-2 in extramammary Paget's disease.
Masuguchi S; Jinnin M; Fukushima S; Makino T; Sakai K; Inoue Y; Igata T; Ihn H
Biosci Trends; 2011 Aug; 5(4):151-5. PubMed ID: 21914949
[TBL] [Abstract][Full Text] [Related]
37. Serum CYFRA 21-1 (cytokeratin-19 fragments) is a useful tumour marker for detecting disease relapse and assessing treatment efficacy in breast cancer.
Nakata B; Takashima T; Ogawa Y; Ishikawa T; Hirakawa K
Br J Cancer; 2004 Aug; 91(5):873-8. PubMed ID: 15280913
[TBL] [Abstract][Full Text] [Related]
38. Serum level of cytokeratin 19 fragment (CYFRA 21-1) indicates tumour stage and prognosis of squamous cell carcinoma of the oesophagus.
Tsuchiya Y; Onda M; Miyashita M; Sasajima K
Med Oncol; 1999 Apr; 16(1):31-7. PubMed ID: 10382940
[TBL] [Abstract][Full Text] [Related]
39. CYFRA 21-1 enzyme-linked immunosorbent assay. Evaluation as a tumor marker in non-small cell lung cancer.
Lai RS; Hsu HK; Lu JY; Ger LP; Lai NS
Chest; 1996 Apr; 109(4):995-1000. PubMed ID: 8635383
[TBL] [Abstract][Full Text] [Related]
40. The role of immunohistochemistry in discriminating primary from secondary extramammary Paget disease.
Perrotto J; Abbott JJ; Ceilley RI; Ahmed I
Am J Dermatopathol; 2010 Apr; 32(2):137-43. PubMed ID: 20051815
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
